Epidemiological investigation and drug resistance analysis of Escherichia coli infection from 2014 to 2019
10.3969/j.issn.1006-2483.2021.01.014
- VernacularTitle:2014—2019年大肠埃希菌感染流行病学调查及耐药性分析
- Author:
Han SUI
1
;
Wu WEN
1
;
Yi JIAN
1
Author Information
1. Department of Gastroenterology, Chengdu Second People's Hospital, Chengdu , Sichuan 610017, China
- Publication Type:Journal Article
- Keywords:
Escherichia coli;
Epidemiology;
Clinical distribution;
Drug resistance
- From:
Journal of Public Health and Preventive Medicine
2021;32(1):55-58
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the epidemiological characteristics and drug resistance of Escherichia coli infection in Chengdu Second People's Hospital from 2014 to 2019. Methods The specimen types, department sources, infection sites and population characteristics of 1 999 strains of Escherichia coli isolated from the hospital from 2014 to 2019 were analyzed. The trend χ2 was used to analyze the annual isolation rate of Escherichia coli and the change of the rate of Escherichia coli resistance to common antibacterial drugs. Results The isolation rate of Escherichia coli showed a downward trend year by year from 2014 to 2019 (P<0.05). From 2014 to 2019, the specimen type with high detection rate of Escherichia coli in the hospital was mainly urine (52.43%), the department was mainly in urology (25.66%), the main infection site was in the urinary tract (50.08%), and the population was mainly those under 65 years old (51.63%) and females (56.43%). Escherichia coli showed high drug resistance to ampicillin, piperacillin, ceftriaxone, levofloxacin and cotrimoxazole. From 2014 to 2019, the resistance rate of Escherichia coli to ampicillin, piperacillin and ceftriaxone increased year by year (χ2trend=16.345, χ2trend=10.697, χ2trend=7.324, P<0.05). Conclusion From 2014 to 2019, the isolation rate of Escherichia coli had a downward trend year by year, but the drug resistance rate of Escherichia coli to ampicillin, piperacillin and ceftriaxone showed an upward trend year by year. In addition to strengthening the monitoring of high-risk sites, departments and population, drug sensitivity tests should also be done to guide rational clinical use.
